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Poster Session II S351adjustment without compromising efficacy. Drug interaction com-
plexity with new agents and lack of pediatric data highlights a need
for collaboration between HSCT units.551
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LEVEL MONITORING IN HEMATOPOIETIC STEM CELL TRANSPLANT RE-
CIPIENTS
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MD Anderson Cancer Center, Houston, TX; 2The University of Texas
MD Anderson Cancer Center, Houston, TX
Background: Patients undergoing hematopoietic stem cell trans-
plant (HSCT) may have a higher incidence of infections due to sec-
ondary hypogammaglobulinemia. A recent meta-analysis evaluated
intravenous immune globulin (IVIG) in a prophylactic setting and
concluded routine use had no benefit in survival or infection preven-
tion inHSCT.The study suggestedmonitoring of IgG levels and re-
placing with IVIG in high risk patients.
Methods: All allogeneic HSCT patients who received prophylactic
IVIG 0.2 gm/kg IV onceweekly (n5 115) from admission to day +90
were compared to patients who received IVIG based on low IgG
levels (n5 114) between 1/09 and 8/09. The IgG levels were drawn
upon admission, day +30, day +60, and day +90. Utilization of IVIG,
incidence of veno-occulsive disease (VOD), graft versus host disease
(GVHD), and documented infections were recorded during the first
100 days after transplant.
Results:The weekly control group (n 5 115) had a median age of
49 compared to 54 years in the IVIG by level group (n 5 114).
No significant difference in type of transplant, except a higher
number of matched un-related donors (MUD) in the by level
group (62 vs 41, p 5 0.01). There were no significant differences
in occurrence of GVHD (55 vs 50), VOD (2 vs 0), or in infections
such as RSV (3 vs 1), VZV (1 vs 0), HSV (3 vs 8), Adenovirus (2 vs
1), polyoma/BK virus (18 vs 26), bacterial infection (49 vs 38), or
fungal infection (12 vs 7) in weekly versus by IgG levels respec-
tively. A higher incidence of para-influenza occurred in the
weekly group (9 vs 0, p 5 0.003) correlating with flu season.
IVIG cost in the weekly control group totaled AWP $924,408
vs $252,547, with overall savings of $671,816 in the IVIG by level
group.
Conclusion:With no difference in major complications, rate of in-
fection, and a significant savings in IVIG use, a change in institu-
tional practice was implemented. IgG levels are now monitored
monthly and replacement is done based on low IgG level.552
RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF SYMPTOMATIC VE-
NOUS THROMBOEMBOLISM AMONG PATIENTS WITH HEMATOLOGIC
MALIGNANCY
Hills, H., Broyles, J., Oliphant, C., Stelts, S. Methodist University Hospi-
tal, Memphis, TN
A growing body of evidence shows similar or increased venous
thromboembolism (VTE) risk in specific hematologic malignancies,
but few recommendations for VTE prophylaxis in hematologic ma-
lignancy exist. This study will investigate the incidence and trends of
VTE among hematologic malignancy patients to identify patients at
higher risk of VTE.
Methods: Clinical data was collected retrospectively from 200 ad-
missions to Methodist University Hospital from December 2008
to October 2009 with primary or secondary diagnoses of hemato-
logic malignancy. The primary objective is the incidence of symp-
tomatic VTE. Secondary objectives include rate of appropriate
VTE prophylaxis, risk of VTE in patients receiving VTE prophy-
laxis, subgroup analyses to determine populations at higher risk for
VTE, length of stay with occurrence of symptomatic VTE, inci-
dence of VTE surrounding implementation of hospital-wide VTE
prophylaxis protocol, and all-cause mortality versus possible VTE-
associated deaths.Results: A total of 144 patients were represented in 200 admis-
sions included in this study. The most common diagnoses
included were non-Hodgkin’s lymphoma (NHL, 24.3%), multi-
ple myeloma (MM, 24.3%), and acute myelocytic leukemia
(AML, 18.1%), and a majority of patients were African Ameri-
can. In April 2009, an automated screening tool for VTE pro-
phylaxis was implemented that both assesses VTE risk and
bleeding risk and offers three elective therapy options for
VTE prophylaxis. Admissions were stratified according to the
implementation date (100 before, 100 after protocol). Twelve
VTE events were observed across all 200 admissions (6%).
Nine VTE occurred prior to the protocol and 3 occurred after
the prophylaxis protocol, not statistically significant. NHL
(13%), chronic myelocytic leukemia (CML, 12.5%), and Hodg-
kin’s lymphoma (HL, 8.3%) had the highest rates of VTE. VTE
prophylaxis use increased by 160% after implementation of the
VTE prophylaxis protocol, (p 5 0.003). Use of VTE prophy-
laxis was not associated with any decreased risk of VTE or
length of stay.
Conclusion: Incidence of VTE among the local malignant hematol-
ogy patient population is similar to previously reported data, with
highest VTE rates found in those patients with NHL, CML, and
HL. The apparent lack of efficacy of VTE prophylaxis in this study
may reflect either inaccurate current definitions of adequate VTE
prophylaxis or the practice of holding anticoagulants in the setting
of thrombocytopenia.553
VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM SURVEILANCE AND
INFECTION IN AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION
Trifilio, S., Mehta, J. Northwestern Memorial Hospital
Introduction: Colonization with Vancomycin-resistant Enterococ-
cus Faecium(VRE) places patients at increased risk for VRE infec-
tion. Variable rates of colonization and infection have been
reported for hematapoeticc stem cell transplantion recipients.
Herein we reivew VRE colonization rates amongst 882 autologous
and allogeniec HSCT recipients and assess for risk factors associated
with the development of VRE infection.
Methods:Medical records for 822 consecutive HSCT recipient in-
patient admissions between 8/2004 to 8/2008were reviewed for data.
Pharmacy records were utilized to obtain data formedication. All pa-
tients were screened for VRE upon admission and weekly thereafter.
All patients received acyclovir, azole antifungals and ciprofloxacin as
prophylaxis. Positive VRE BAL cultures were excluded from infec-
tion analysis. Chi-square analysis was used for statistical analysis.
This study was approved by NMH IRB.
Results:For 822HSCT recipients reviewed (207 allogeneic and 615
autologous), new colonization developed in 136 patients (17%),
while 41 patients were VRE colonized prior to admission. Overall
28 patients (3.4%) developed VRE infection (urine 5 11, blood 5
17, multiple 5 3. No correlation was observed between age, sex,
or administration of a neutropenic diet and VRE colonization or in-
fection. Allogeneic transplant(p5 .013), especially melphalan based
RIST was associated with increased VRE infection (p 5 .011). Co-
infection wth Strept Viridans occurred more frequently in VRE in-
fected patients(p 5 .0001). Prior VRE colonization occurred in
15/28 patients (54%) who developed VRE infection compared to
13/651 who did not.(p 5 .0001). Median time to infection was
10days. A correlation between C.Diff infection and VRE coloniza-
tion was identified(p 5 .0014). Almost all patients received wide
spectrum B-Lactam antibiotics and vancomycin, which may explain
the lack of correlation between these antibiotics and the develop-
ment of VRE, however prior exposure to caspofungin was observed
more frequently in patients with VRE infection(p 5 .0001). All
treated patients received linezolid. Time to engraft was the same
for auto and all patients, with or without VRE. Crude in-patient
overall mortality was significantly higher in patients with VRE
infections (p 5 .0002).
Conclusion: VRE colonization and infection increase morbidity
and mortality post HSCT. Heightened awareness and correction
